MedWatch

Japanese approval strategically important for ALK

Last week, Danish allergy group ALK obtained Japanese authorities’ approval for using a tablet vaccine, too. It fuels the company’s hope that the same approval can be achieved in other markets. However, the rival Stallergenes made the same move so the competition continues to be fierce.

Last week, through its Japanese partner Torii, allergy- and immunotherapy group ALK got a green light in Japan for using the tablet vaccine Miticure against house-dust mite allergy for treatment of children.

Miticure is marketed under the names Odactra in the US and Acarizax in Europe, Singapore, and Australia and it is ALK’s highest hope. Since 2015, the drug has been accessible to Japanese people age 12-64 suffering from allergic rhinitis because of house-dust mites.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier